{"id":745057,"date":"2015-12-18T08:00:00","date_gmt":"2015-12-18T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/"},"modified":"2025-11-07T01:24:42","modified_gmt":"2025-11-07T06:24:42","slug":"merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/","title":{"rendered":"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the Committee for Medicinal Products for Human Use<br \/>\n      (CHMP) of the European Medicines Agency (EMA) has responded to the<br \/>\n      company\u2019s marketing authorization application (MAA) for<br \/>\n      elbasvir\/grazoprevir (50mg\/100mg), which is under review for the<br \/>\n      treatment of adult patients with chronic hepatitis C (HCV) infection.<br \/>\n      The CHMP advised Merck that the application will now be reviewed on a<br \/>\n      standard timetable, rather than the accelerated assessment timeline<br \/>\n      previously announced. Under the revised timeline, Merck anticipates a<br \/>\n      European Commission decision in mid-2016.\n    <\/p>\n<p>\n      \u201cWe are excited about the potential of elbasvir\/grazoprevir and look<br \/>\n      forward to continuing our discussions with the European Medicines Agency<br \/>\n      to bring this important medicine to appropriate patients with chronic<br \/>\n      hepatitis C in the European Union,\u201d said Dr. Roy Baynes, senior vice<br \/>\n      president and head of global clinical development, Merck Research<br \/>\n      Laboratories.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=44e93363bf29974dec32f580b86000b8\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=3566b9d5c168e89c79c62ee8dd37ce9c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b4c171850001ac1e9680ad68f9120d65\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=3195c106ce3c5e0a0b4cd5e2e0c778c2\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=0f113c000da4d0109e929585e0bc5686\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co. Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51245251&amp;newsitemid=20151218005008&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=dc160dbae097128acf781c77ffa84528\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151218005008r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company\u2019s marketing authorization application (MAA) for elbasvir\/grazoprevir (50mg\/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. The CHMP advised Merck that the application will now be reviewed on a standard timetable, rather than the accelerated assessment timeline previously announced. Under the revised timeline, Merck anticipates a European Commission decision in mid-2016. \u201cWe are excited about the potential of elbasvir\/grazoprevir and look forward to continuing our discussions with the European Medicines Agency to bring this important medicine to appropriate patients with chronic hepatitis C in the European Union,\u201d said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289,56],"class_list":["post-745057","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company\u2019s marketing authorization application (MAA) for elbasvir\/grazoprevir (50mg\/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. The CHMP advised Merck that the application will now be reviewed on a standard timetable, rather than the accelerated assessment timeline previously announced. Under the revised timeline, Merck anticipates a European Commission decision in mid-2016. \u201cWe are excited about the potential of elbasvir\/grazoprevir and look forward to continuing our discussions with the European Medicines Agency to bring this important medicine to appropriate patients with chronic hepatitis C in the European Union,\u201d said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\\\/\",\"name\":\"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\\\/Grazoprevir - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-18T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\\\/Grazoprevir\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/","og_locale":"en_US","og_type":"article","og_title":"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has responded to the company\u2019s marketing authorization application (MAA) for elbasvir\/grazoprevir (50mg\/100mg), which is under review for the treatment of adult patients with chronic hepatitis C (HCV) infection. The CHMP advised Merck that the application will now be reviewed on a standard timetable, rather than the accelerated assessment timeline previously announced. Under the revised timeline, Merck anticipates a European Commission decision in mid-2016. \u201cWe are excited about the potential of elbasvir\/grazoprevir and look forward to continuing our discussions with the European Medicines Agency to bring this important medicine to appropriate patients with chronic hepatitis C in the European Union,\u201d said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/","name":"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-18T08:00:00+00:00","dateModified":"2025-11-07T06:24:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-provides-update-on-european-medicines-agency-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-elbasvir-grazoprevir\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir\/Grazoprevir"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3a135fbd-63bc-455d-b870-1449edfc5af5","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745057\/revisions"}],"predecessor-version":[{"id":3674556,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745057\/revisions\/3674556"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745057"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}